Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (Nasdaq: EQ) is a La Jolla, California–based clinical-stage biotechnology company that publicly describes its focus as developing novel therapies for severe autoimmune and inflammatory disorders. News about Equillium often centers on the progress of its lead candidate EQ504, an investigational aryl hydrocarbon receptor (AhR) modulator, and on corporate actions that support its development strategy.
Readers of this EQ news page can follow company announcements on clinical and preclinical plans for EQ504, including preparations for Phase 1 studies in ulcerative colitis and related gastrointestinal conditions, as well as potential applications in inflammatory lung or pulmonary diseases. Equillium’s press releases also highlight scientific and translational updates, such as key opinion leader events discussing AhR modulation, intestinal inflammation and the unmet medical need in ulcerative colitis.
In addition to pipeline news, Equillium regularly reports on financing transactions like private placements and at-the-market offerings, which it links to funding the development of EQ504 and extending its operating runway. Corporate governance and leadership updates, including changes in board composition, committee membership and senior roles, are disclosed through both SEC filings and news releases.
Another recurring topic in Equillium’s news flow is its cryptocurrency treasury reserve strategy, which the company has described as part of its broader financial and growth objectives. Updates in this area appear alongside information on cash resources, investment policy changes and strategic priorities.
Investors and observers can use this news feed to monitor Equillium’s clinical plans, scientific positioning around AhR modulation, capital-raising activities, Nasdaq listing developments and treasury strategy, all of which shape the company’s path as a clinical-stage biotech focused on immuno-inflammatory diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Equillium, Inc. (NASDAQ: EQ) presented positive results from its EQUATE study at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation. The study analyzed the use of itolizumab combined with systemic corticosteroids in treating acute graft-versus-host disease (aGVHD). The findings showed significant clinical responses and improved progression-free survival rates over one year. Itolizumab demonstrated a favorable safety profile and may reduce corticosteroid usage by 99% within six months. Following this data, the pivotal Phase 3 EQUATOR study of itolizumab is underway, targeting first-line treatment of aGVHD, a condition with no approved first-line therapies.
Equillium, Inc. (Nasdaq: EQ) reported a cash balance of $71.0 million at the end of 2022, ensuring funding through 2025. The company acquired Bioniz Therapeutics, enhancing its pipeline with EQ101 and EQ102, both in clinical trials.
Equillium received $26.4 million upfront from a partnership with Ono Pharmaceutical, with an additional $139 million in potential milestone payments. Revenue for Q4 2022 reached $15.8 million, a significant increase from zero in 2021. However, the net loss for the full year was $62.4 million, up from $39.1 million in 2021. The company anticipates key clinical data releases in the second half of 2023.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, at 10:30 am PT. The presentation will focus on the company's expertise in autoimmune diseases and its lead candidate, EQ101, a tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15, currently in a Phase 2 study for alopecia areata. Management will also be available for one-on-one meetings. A live webcast will be accessible on the company's website, with a replay available for 90 days.
Equillium, Inc. (Nasdaq: EQ) has announced positive results from its EQUATE study on Itolizumab, a targeted therapy for acute graft-versus-host disease (aGVHD). The presentation at the American Society of Transplantation and Cellular Therapy showed high clinical response rates with a 70% reduction in steroid use at Day 29 and a remarkable 99% taper at Day 169. These findings suggest potential for Itolizumab as a first-line treatment in severe aGVHD, with the initiation of the pivotal Phase 3 EQUATOR study.
Dr. Koreth emphasized the significance of these results, considering the lack of approved first-line treatments for aGVHD.
Equillium, Inc. (NASDAQ: EQ) announced its participation in the SVB Securities Global Biopharma Conference on February 14 at 10:00 am PT. The presentation will cover the recent partnership with Ono Pharmaceuticals and details on its multi-cytokine inhibitor platform, including EQ101 for alopecia areata and EQ102 for celiac disease. Management will also discuss upcoming catalysts and will be available for one-on-one meetings. The webcast can be accessed via the Investor Relations section of Equillium’s website, and a replay will be available for 90 days.
Equillium, Inc. (Nasdaq: EQ) announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings, taking place from February 15-19, 2023, in Orlando, Florida. The presentation, titled "Final Safety and Efficacy Results from EQUATE," details the promising findings of a Phase 1b study of itolizumab for treating newly diagnosed acute graft-versus-host disease (aGVHD).
The study shows significant outcomes, including long-term follow-ups up to one year. Following these results, Equillium has initiated EQUATOR, a Phase 3 study to evaluate itolizumab as a potential first-line treatment.